Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma

Abstract Background Current understanding of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) lacks high-level evidence. This study provides additional efficacy data for this treatment regimen. Methods Clinical trials investigating neoadjuvant tislelizuma...

Cijeli opis

Bibliografski detalji

Glavni autori:	Hao Yin, Xinyu Yang, Yujie Chen, Hongtao Duan, Jie Wang, Xuqiang Liao, Guangyu Yao, Fei Liang, Hong Fan, Gao Li, Yihua Sun, Xiaolong Yan, Peiyuan Wang, Lijie Tan
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer 2025-12-01
Serija:	Cancer Immunology, Immunotherapy
Teme:	Neoadjuvant Tislelizumab plus chemotherapy Advanced esophageal squamous cell carcinoma
Online pristup:	https://doi.org/10.1007/s00262-025-04240-8
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!